1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

• Martin Oft,
• Michael Totagrande,
• Luis Zuniga,
• David B Rosen,
• Priyanka Balasubrahmanyam,
• Zhenya Koliesnik,
• Ryan Burgess,
• Kim Q Tran,
• Michele Bauer,
• Bharghavi Jayaraman,
• Cindy Buffone,
• Jan Emmerich,
• Deepti Chaturvedi,
• Deepti Rokkam,
• Rene De Waal Malefyt,
• Heiko Greb,
• Navneet Ratti,
• Sandro Vivona,
• Robert Kastelein,
• Patrick Lupardus

Affiliations

Martin Oft

1Synthekine, Menlo Park, CA, USA

Michael Totagrande

1Synthekine, Menlo Park, CA, USA

Luis Zuniga

1Synthekine, Menlo Park, CA, USA

David B Rosen

1Synthekine, Menlo Park, CA, USA

Priyanka Balasubrahmanyam

1Synthekine, Menlo Park, CA, USA

Zhenya Koliesnik

1Synthekine, Menlo Park, CA, USA

Ryan Burgess

1Synthekine, Menlo Park, CA, USA

Kim Q Tran

1Synthekine, Menlo Park, CA, USA

Michele Bauer

1Synthekine, Menlo Park, CA, USA

Bharghavi Jayaraman

1Synthekine, Menlo Park, CA, USA

Cindy Buffone

1Synthekine, Menlo Park, CA, USA

Jan Emmerich

2Synthekine, Germany

Deepti Chaturvedi

1Synthekine, Menlo Park, CA, USA

Deepti Rokkam

1Synthekine, Menlo Park, CA, USA

Rene De Waal Malefyt

1Synthekine, Menlo Park, CA, USA

Heiko Greb

1Synthekine, Menlo Park, CA, USA

Navneet Ratti

1Synthekine, Menlo Park, CA, USA

Sandro Vivona

1Synthekine, Menlo Park, CA, USA

Robert Kastelein

1Synthekine, Menlo Park, CA, USA

Patrick Lupardus

1Synthekine, Menlo Park, CA, USA